Feb. 28, 2013
/PRNewswire/ - Invaron Pharmaceuticals Inc. clinical partner, the Center for Assisted Reproduction (CARE), led by
Kevin Doody M.D
., today initiated an investigator led, IRB approved Phase III study using INVOcell
in patients with tubal blockage or unexplained infertility that require in vitro fertilization.
is an innovative medical device used in infertility treatment which enables conception and early embryo development to occur within a woman's own body rather than in a laboratory. "The primary focus of the study will be to first evaluate the comfort and retention of the system over 5 days to ensure that INVOcell
performs similarly to existing 3 day retention data," remarked Dr.
. "We will then examine how INVOcell
compares to conventional IVF in an open label extension, examining the quality day 5 embryos, known as blastocysts, and ultimately pregnancy and live birth rates".
"We are excited at the prospect of partnering with CARE and Dr.
as part of our Phase III/IV clinical program in
the United States
, President and COO of Invaron Pharmaceuticals. "IVF is increasingly utilizing day 5 embryo culture and this data will ultimately serve to broaden the use of INVOcell
Patients interested in learning more are encouraged to contact the Center for Assisted Reproduction in
About Invaron Pharmaceuticals
Invaron is a Canadian based pharmaceutical company focusing exclusively on the acquisition of niche drugs and medical devices registered in other countries but not in
. By facilitating local registration, bridging clinical gaps, and launching innovative marketing strategies, Invaron will effectively meet the under serviced needs of Canadian patients in a wide variety of therapeutic areas. Invaron encourages patients, physicians, potential pharmaceutical partners and other stakeholders to visit
to learn more.
About the Centre for Assisted Reproduction (CARE)